HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary
immunogenic target for virus neutralization and the current focus of many vaccine design …

The development of stabilized recombinant HIV envelope trimers that mimic the virion
surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV …

The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible,
fluctuating between closed and more open conformations and sometimes sampling the fully …

Structure determination of the HIV‐1 envelope glycoprotein (Env) presented a number of
challenges, but several high‐resolution structures have now become available. In 2013 …

We describe the development and potential use of various designs of recombinant HIV‐1
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …

Broadly neutralizing antibodies (bnAbs) are thought to be a critical component of a
protective HIV vaccine. However, designing vaccines immunogens able to elicit bnAbs has …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable
templates for vaccine design, and studies of the immunological development of these …

Structures of BG505 SOSIP. 664 trimer in complex with broadly neutralizing antibodies
(bNAbs) have revealed the critical role of trimeric context for immune recognition of HIV-1 …